Recursion Pharmaceuticals, Inc. RXRX R2KR3KAIPHARMA
Company Overview
Recursion Pharmaceuticals, Inc., a clinical-stage biotechnology company, engages in the decoding biology and chemistry by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery in the United States and the United Kingdom. The company develops REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-617, which is in Phase 1/2 clinical trial to treat advanced solid tumors; REC-1245, which is in Phase 1/2 clinical trial to treat biomarker-enriched solid tumors and lymphoma; REC-3565 that is in Phase 1/2 for the treatment of relapsed or refractory B-cell malignancies; and REC-4539, a reversible, CNS penetrant, orally bioavailable, and potential best-in-class inhibitor of LSD1 for the treatment of solid tumors and hematology oncology. Its preclinical stage product includes REC-7735 for the treatment of HR+ breast cancer; and REC-102 for the treatment of hypophosphatasia. The company has collaboration and agreement with Roche & Genentech; Sanofi; Bayer AG; Tempus; and Takeda Pharmaceutical Company Limited. Recursion Pharmaceuticals, Inc. was incorporated in 2013 and is headquartered in Salt Lake City, Utah.
Why Investors Should Care
Revenue has grown at a 78.4% CAGR over the past five years.
Carries low leverage with a debt-to-equity ratio of 0.07.
Recent Developments
- Dec 2025 Revenue of $74.68M (+26.9% YoY); net profit $-644.76M.
- Trailing 12 Months Year-on-year growth — revenue -60.1%.
- 5-Year Trend Long-term compounding — revenue CAGR 78.4%.
Growth & Price Performance
Compounded Sales Growth
| 5 Years: | 78.37% |
| 1 Year: | -60.10% |
Stock Price Performance
| 1 Year: | -36.32% |
| 6 Months: | +4.91% |
| 3 Months: | +9.50% |
| 1 Month: | +14.15% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
Phenomic-image foundation models for drug discovery; merged with Exscientia.
- AI-driven drug discovery Recursion runs a 'lab-in-the-loop' platform combining automated biology experiments with machine learning to discover drugs at scale.
- BioHive supercomputing Its NVIDIA-backed BioHive supercomputer trains models on vast proprietary biological datasets.
- Pharma partnerships Collaborations with major pharma validate and fund the AI-discovery platform.
- A leading 'AI for biology' platform with a large proprietary dataset and NVIDIA backing.
- Pre-commercial and deeply loss-making — a long-duration optionality bet.
- Pipeline progress and partnership milestones are the key catalysts.
- High-risk: drug-discovery timelines are long and uncertain; needs ongoing funding.
Curated from public filings and analyst commentary; figures are illustrative.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
- Compounding revenue at 78.4% over 5 years.
CONS
- Trading 46.5% below its 52-week high.
- In a downtrend (50-DMA below 200-DMA).
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | RXRX Recursion Pharmaceuticals, Inc. R2KR3KAIPHARMA | 3.63 | -3.63 | $1.94B | 0.00% | -48.86% | -56.58% | 78.37% | - |
| 2 | LLY Eli Lilly and Company SPXR3KPHARMA | 1,149.36 | 38.57 | $1.02T | 0.58% | - | 102.29% | 7.20% | 11.41% |
| 3 | JNJ Johnson & Johnson SPXR3KPHARMA | 275.23 | 31.97 | $663.28B | 2.09% | 14.88% | 25.74% | 2.43% | 4.76% |
| 4 | ABBV AbbVie Inc. SPXR3KPHARMA | 256.46 | 72.45 | $453.19B | 2.84% | 10.47% | -129.24% | 1.75% | -29.06% |
| 5 | MRK Merck & Co., Inc. SPXR3KPHARMA | 150.33 | 120.26 | $371.29B | 2.65% | - | 34.70% | 5.64% | 10.01% |
| 6 | UNH UnitedHealth Group Incorporated SPXR3KPHARMA | 397.14 | 25.54 | $356.47B | 2.33% | 9.74% | 14.15% | 10.40% | 5.43% |
| 7 | NVS Novartis AG PHARMA | 159.99 | 24.20 | $304.10B | 3.03% | 21.09% | 30.35% | 9.25% | 26.22% |
| 8 | AZN AstraZeneca PLC NDXPHARMA | 162.70 | 24.36 | $252.33B | 1.98% | 15.97% | 21.96% | 9.82% | 45.96% |
| 9 | AMGN Amgen Inc. NDXSPXR3KPHARMA | 437.23 | 27.14 | $235.98B | 2.49% | 13.95% | 91.47% | 5.51% | 5.55% |
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Mar 2020 | Jun 2020 | Sep 2020 | Mar 2021 | Jun 2021 | Sep 2021 | Mar 2022 | Jun 2022 | Sep 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 60.00K | 186.00K | 1.02M | 2.56M | 2.55M | 2.53M | 5.33M | 7.67M | 13.16M | 12.13M | 11.02M | 10.53M | 13.79M | 14.42M | 26.08M | 14.74M | 19.22M | 5.17M | 6.47M | 7.67M |
| Operating Income | -18.34M | -18.22M | -22.47M | -30.48M | -40.93M | -46.40M | -55.98M | -66.19M | -62.57M | -69.86M | -81.72M | -99.55M | -96.34M | -100.54M | -98.35M | -191.37M | -176.23M | -172.20M | -128.50M | -134.97M |
| Net Income | -18.42M | -18.94M | -23.87M | -30.72M | -43.40M | -47.43M | -55.98M | -65.56M | -60.45M | -65.33M | -76.73M | -93.02M | -91.37M | -97.54M | -95.84M | -202.49M | -171.90M | -162.25M | -117.50M | -131.00M |
| Diluted EPS | -0.85 | -0.88 | -1.09 | -1.33 | -0.31 | -0.28 | -0.33 | -0.38 | -0.35 | -0.34 | -0.38 | -0.43 | -0.39 | -0.40 | -0.34 | -0.50 | -0.41 | -0.36 | -0.22 | -0.25 |
| R&D Expense | 12.84M | 13.24M | 16.54M | 24.11M | 29.62M | 33.25M | 32.44M | 38.44M | 40.84M | 46.68M | 55.06M | 70.01M | 67.56M | 73.93M | 74.60M | 129.63M | 128.64M | 121.06M | 87.90M | 89.61M |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|
| Revenue | 2.32M | 3.96M | 10.18M | 39.84M | 44.58M | 58.84M | 74.68M |
| Operating Income | -62.44M | -84.61M | -182.78M | -245.73M | -350.06M | -479.00M | -648.13M |
| Net Income | -61.88M | -87.01M | -186.48M | -239.48M | -328.07M | -463.66M | -644.76M |
| Diluted EPS | -2.87 | -3.99 | -1.49 | -1.36 | -1.58 | -1.69 | -1.44 |
| R&D Expense | 45.81M | 63.32M | 135.27M | 155.70M | 241.23M | 314.42M | 475.27M |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|
| Total Assets | - | - | 298.58M | 610.35M | 701.29M | 653.70M | 1.45B | 1.47B |
| Total Equity | -63.85M | -124.27M | -206.29M | 542.94M | 485.81M | 463.44M | 1.03B | 1.13B |
| Cash & Equivalents | - | - | 262.13M | 285.12M | 549.91M | 391.56M | 594.35M | 743.29M |
| Long Term Debt | - | - | - | 723.00K | - | - | - | - |
| Total Liabilities | - | - | 56.56M | 67.41M | 215.48M | 190.26M | 413.82M | 343.26M |
| Current Liabilities | - | - | 23.10M | 46.66M | 100.27M | 93.17M | 187.47M | 147.71M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -57.04M | -45.40M | -158.61M | -83.52M | -287.78M | -359.17M | -371.81M |
| Investing Cash Flow | -3.91M | -8.74M | -271.74M | 193.25M | -10.23M | 260.06M | -16.87M |
| Financing Cash Flow | 120.41M | 246.13M | 458.54M | 154.34M | 140.13M | 304.12M | 521.53M |
| Capital Expenditure | -3.91M | -5.83M | -39.80M | -37.06M | -11.96M | -13.70M | -6.47M |
| Free Cash Flow | -60.95M | -51.23M | -198.41M | -120.58M | -299.74M | -372.87M | -378.28M |
Ratios (Annual)
Figures in %.
| Metric | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|
| Gross Margin % | - | - | - | - | - | - | - |
| Operating Margin % | -2,692.6% | -2,135.7% | -1,795.8% | -616.7% | -785.3% | -814.1% | -867.9% |
| Net Margin % | -2,668.3% | -2,196.0% | -1,832.2% | -601.0% | -736.0% | -788.0% | -863.4% |
| ROE % | 49.8% | 42.2% | -34.3% | -49.3% | -70.8% | -44.8% | -57.0% |
| ROCE % | - | -30.7% | -32.4% | -40.9% | -62.5% | -38.0% | -48.9% |
Shareholding Pattern
Top Institutional Holders
| # | Holder | % Held | Shares | Value |
|---|---|---|---|---|
| 1 | Blackrock Inc. | 9.40% | 50.30M | $168.02M |
| 2 | ARK Investment Management, LLC | 7.72% | 41.34M | $138.07M |
| 3 | State Street Corporation | 6.48% | 34.71M | $115.92M |
| 4 | Vanguard Portfolio Management LLC | 5.82% | 31.13M | $103.98M |
| 5 | BAILLIE GIFFORD & CO | 4.39% | 23.49M | $78.45M |
| 6 | Vanguard Capital Management LLC | 4.25% | 22.77M | $76.04M |
| 7 | Geode Capital Management, LLC | 2.58% | 13.82M | $46.16M |
| 8 | Softbank Group Corporation | 2.55% | 13.64M | $45.55M |
| 9 | MIC Capital Management UK LLP | 1.80% | 9.64M | $32.21M |
| 10 | UBS Group AG | 1.67% | 8.95M | $29.88M |
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for RXRX
The Zacks Analyst Blog Highlights Recursion Pharmaceuticals, Schrodinger, Relay Therapeutics and Absci
AI is reshaping drug discovery, with Recursion Pharmaceuticals, Schrodinger, Relay Therapeutics and Absci advancing computational platforms and pipelines.
Contineum, Disc Medicine, Recursion Advance Pipelines Ahead of Catalysts, Morgan Stanley Says
Contineum Therapeutics (CTNM), Disc Medicine (IRON), and Recursion Pharmaceuticals (RXRX) are making
Recursion Pharmaceuticals Highlights AI Platform, Roche Progress and Pipeline Updates
Recursion Pharmaceuticals (NASDAQ:RXRX) is using artificial intelligence to generate and analyze biological data in an effort to improve drug discovery, advance internal therapeutic programs and support collaborations with larger pharmaceut…
These Are the Stocks Wall Street Is Betting Against the Most
Wolfspeed, BigBear.ai and Others Face Heavy Short-Seller Pressure
Recursion (RXRX) Q2 2026 Earnings Call Transcript
AI-native drug discovery advances neuroscience target with Roche while cutting cash guidance.
Recursion Pharmaceuticals Q2 Earnings Call Highlights
Recursion Pharmaceuticals (NASDAQ:RXRX) outlined progress across its clinical pipeline, drug-discovery partnerships and AI-enabled research platform, while lowering its 2026 cash operating expense guidance to $375 million and reaffirming ex…
RXRX — Frequently Asked Questions
What is the current share price of Recursion Pharmaceuticals, Inc. (RXRX)?
As of 2026-09-07 16:24 PDT, Recursion Pharmaceuticals, Inc. (RXRX) trades at $3.63 on NasdaqGS. Its 52-week range is $2.84 to $6.79.
What is the market capitalisation of RXRX?
Recursion Pharmaceuticals, Inc. (RXRX) has a market capitalisation of $1.94B on NasdaqGS.
What is the P/E ratio of RXRX?
RXRX trades at a trailing price-to-earnings (P/E) ratio of -3.63. The industry average P/E is 25.17. Its price-to-book (P/B) ratio is 1.87.
What is the return on equity (ROE) of RXRX?
RXRX has a return on equity (ROE) of -56.58%. Its return on capital employed (ROCE) is -48.86%.
Is RXRX a good stock to buy?
This page provides a data-driven analysis of Recursion Pharmaceuticals, Inc. (RXRX), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.